PL2086939T3 - Pirydynokarboksyamidy jako inhibitory 11-beta-hsd1 - Google Patents

Pirydynokarboksyamidy jako inhibitory 11-beta-hsd1

Info

Publication number
PL2086939T3
PL2086939T3 PL07824375T PL07824375T PL2086939T3 PL 2086939 T3 PL2086939 T3 PL 2086939T3 PL 07824375 T PL07824375 T PL 07824375T PL 07824375 T PL07824375 T PL 07824375T PL 2086939 T3 PL2086939 T3 PL 2086939T3
Authority
PL
Poland
Prior art keywords
beta
hsd1 inhibitors
pyridine carboxamides
carboxamides
pyridine
Prior art date
Application number
PL07824375T
Other languages
English (en)
Polish (pl)
Inventor
William Mccoull
Martin Packer
James Stewart Scott
Paul Robert Owen Whittamore
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PL2086939T3 publication Critical patent/PL2086939T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
PL07824375T 2006-11-03 2007-10-31 Pirydynokarboksyamidy jako inhibitory 11-beta-hsd1 PL2086939T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86424706P 2006-11-03 2006-11-03
US86430306P 2006-11-03 2006-11-03
PCT/GB2007/004131 WO2008053194A2 (en) 2006-11-03 2007-10-31 Pyridine carboxamides as 11-beta-hsd1 inhibitors
EP07824375A EP2086939B8 (en) 2006-11-03 2007-10-31 Pyridine carboxamides as 11-beta-hsd1 inhibitors

Publications (1)

Publication Number Publication Date
PL2086939T3 true PL2086939T3 (pl) 2011-09-30

Family

ID=39304797

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07824375T PL2086939T3 (pl) 2006-11-03 2007-10-31 Pirydynokarboksyamidy jako inhibitory 11-beta-hsd1

Country Status (30)

Country Link
US (3) US7964618B2 (enExample)
EP (2) EP2086939B8 (enExample)
JP (1) JP5165688B2 (enExample)
KR (1) KR101465275B1 (enExample)
CN (3) CN101573336B (enExample)
AR (1) AR063458A1 (enExample)
AT (1) ATE475649T1 (enExample)
AU (1) AU2007315955B2 (enExample)
BR (1) BRPI0717970C1 (enExample)
CA (1) CA2668006C (enExample)
CL (1) CL2007003176A1 (enExample)
CO (1) CO6321130A2 (enExample)
CY (1) CY1110813T1 (enExample)
DE (1) DE602007008137D1 (enExample)
DK (1) DK2086939T3 (enExample)
ES (2) ES2347491T3 (enExample)
HR (1) HRP20100522T1 (enExample)
IL (1) IL198231A0 (enExample)
MX (1) MX2009004707A (enExample)
NO (1) NO20091603L (enExample)
NZ (1) NZ576501A (enExample)
PE (1) PE20081487A1 (enExample)
PL (1) PL2086939T3 (enExample)
PT (1) PT2086939E (enExample)
RS (1) RS51451B (enExample)
RU (1) RU2451674C2 (enExample)
SI (1) SI2086939T1 (enExample)
TW (1) TW200827346A (enExample)
UY (1) UY30681A1 (enExample)
WO (1) WO2008053194A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101024227B1 (ko) 2005-11-21 2011-03-29 시오노기세이야쿠가부시키가이샤 11-β-히드록시스테로이드 탈수소효소 제 Ⅰ 형에 대한저해 활성을 갖는 헤테로시클릭 화합물
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
TW200836719A (en) * 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
CN103288738B (zh) 2007-05-18 2016-03-16 盐野义制药株式会社 具有11β-羟基类固醇脱氢酶I型抑制活性的含氮杂环衍生物
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP5441705B2 (ja) 2007-10-15 2014-03-12 武田薬品工業株式会社 アミド化合物およびその用途
WO2009056881A1 (en) * 2007-10-29 2009-05-07 Astrazeneca Ab Chemical compounds 313
MX2010008583A (es) * 2008-02-04 2010-08-30 Astrazeneca Ab Novedosos formas cristalinas de acido 4-[4-(2-adamantilcarbamoil)- 5-ter-butil-pirazol-1-il]benzoico.
AU2009239794A1 (en) * 2008-04-22 2009-10-29 Astrazeneca Ab Substituted pyrimidin-5-carboxamides 281
EP2243479A3 (en) 2009-04-20 2011-01-19 Abbott Laboratories Novel amide and amidine derivates and uses thereof
CN102458402B (zh) 2009-06-12 2013-10-02 百时美施贵宝公司 用作激酶调节剂的烟酰胺化合物
US20110092526A1 (en) * 2009-10-20 2011-04-21 Astrazeneca Ab Adamantyl Iminocarbonyl-Substituted Pyrimidines As Inhibitors Of 11-Beta-HSD1 826
IN2012DN05125A (enExample) * 2009-11-24 2015-10-23 Allergan Inc
US8871208B2 (en) * 2009-12-04 2014-10-28 Abbvie Inc. 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
KR20110123657A (ko) * 2010-05-07 2011-11-15 에스케이케미칼주식회사 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
CA2809675A1 (en) 2010-09-23 2012-03-29 Shuang Chen Monohydrate of an azaadamantane derivative
US8471027B2 (en) * 2011-04-06 2013-06-25 Hoffmann-La Roche Inc. Adamantyl compounds
EP2735567B1 (en) * 2011-07-21 2016-10-26 Xuanzhu Pharma Co., Ltd. Heterocyclic substituted pyrimidine compound
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN102659657B (zh) * 2012-04-24 2014-08-06 徐州医学院 一种蛋白酶抑制剂pf429242的合成方法
AU2013279510A1 (en) 2012-06-20 2014-10-16 F. Hoffmann-La Roche Ag Substituted pyrazole compounds as LPAR antagonists
EP2864300A1 (en) 2012-06-20 2015-04-29 F. Hoffmann-La Roche AG N-alkyltriazole compounds as lpar antagonists
EP3821892A1 (en) 2019-11-12 2021-05-19 University of Leeds (s)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl) acetic acid for use in treating wounds
GB202216324D0 (en) * 2022-11-02 2022-12-14 Cerevance Ltd Novel compounds

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR66581B (enExample) 1978-02-21 1981-03-27 Delalande Sa
US4734418A (en) 1984-12-14 1988-03-29 Mitsui Petrochemical Industries, Ltd. Quinazoline compounds and antihypertensives
IL148291A0 (en) 1999-09-16 2002-09-12 Tanabe Seiyaku Co Aromatic nitrogen-containing 6-membered cyclic compounds
FR2803592A1 (fr) * 2000-01-06 2001-07-13 Aventis Cropscience Sa Nouveaux derives de l'acide 3-hydroxypicolinique, leur procede de preparation et compositions fongicides les contenant.
US7273868B2 (en) 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
US6777446B2 (en) 2000-09-05 2004-08-17 Tularik, Inc. FXR modulators
NZ526003A (en) 2000-10-20 2005-09-30 Biocryst Pharm Inc Biaryl compounds as serine protease inhibitors
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
EP1492541A1 (en) 2002-04-05 2005-01-05 The University Of Edinburgh Pharmaceutical compositions comprising a 11-beta hydroxysteroid dehydrogenase inhibitor and a diuretic agent
WO2004039795A2 (en) * 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Amide compounds for the treatment of hyperlipidemia
TW200503994A (en) * 2003-01-24 2005-02-01 Novartis Ag Organic compounds
SE0300457D0 (sv) * 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
SE0300458D0 (sv) * 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
EP1600442B1 (en) 2003-02-26 2018-01-17 Msd K.K. Heteroarylcarbamoylbenzene derivative
JP4629657B2 (ja) 2003-04-11 2011-02-09 ハイ・ポイント・ファーマスーティカルズ、エルエルシー １１β−ヒドロキシステロイドデヒドロゲナーゼ１型化活性化合物
WO2005016877A2 (en) 2003-08-07 2005-02-24 Merck & Co., Inc. Pyrazole carboxamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
CN102060806A (zh) 2003-09-11 2011-05-18 iTherX药品公司 细胞因子抑制剂
GB0327761D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
KR20060101772A (ko) 2003-12-19 2006-09-26 화이자 인코포레이티드 당뇨병 및 비만을 치료하기 위한,11-베타-하이드록시스테로이드 데하이드로게나제 유형1(11-베타-ｈｓｄ-1)의 저해제로서의벤젠설폰일아미노-피리딘-2-일 유도체 및 관련 화합물
JP2007523206A (ja) 2004-02-24 2007-08-16 グラクソ　グループ　リミテッド Ｃｂ２受容体モジュレーターとしてのピリジン誘導体およびその使用
CN1972914A (zh) * 2004-03-31 2007-05-30 詹森药业有限公司 作为组胺h3受体配合体的非咪唑杂环化合物
JP2007536369A (ja) 2004-05-06 2007-12-13 ファイザー・インク プロリン及びモルホリン誘導体の新規化合物
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
DK1763517T3 (da) 2004-06-28 2011-06-06 Hoffmann La Roche Pyrimidinderivater som 11beta-HSD1-inhibitorer
CA2585735A1 (en) 2004-11-02 2006-05-11 Pfizer Inc. Novel compounds of substituted and unsubstituted adamantyl amides
JP2008519034A (ja) 2004-11-03 2008-06-05 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネル調節剤としてのピリミジン誘導体および使用方法
KR101496206B1 (ko) 2005-01-05 2015-02-27 애브비 인코포레이티드 11-베타-하이드록시스테로이드 데하이드로게나제 타입 1 효소의 억제제로서의 아다만틸 유도체
WO2006106052A1 (en) 2005-04-05 2006-10-12 F. Hoffmann-La Roche Ag Pyrazoles
CN101155781B (zh) 2005-04-06 2012-11-07 霍夫曼-拉罗奇有限公司 作为cb1逆激动剂的吡啶-3-甲酰胺衍生物
WO2006106423A2 (en) 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
EP2527337A1 (en) 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
WO2006125958A1 (en) 2005-05-24 2006-11-30 Astrazeneca Ab 2-phenyl substituted imidazol [4 , 5b] pyridine/ pyrazine and purine derivatives as glucokinase modulators
TW200716576A (en) 2005-06-07 2007-05-01 Shionogi & Co Heterocyclic derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
KR100970294B1 (ko) 2005-06-08 2010-07-15 니뽄 다바코 산교 가부시키가이샤 복소환 화합물
DE602006010546D1 (de) 2005-06-16 2009-12-31 Pfizer N-(pyridin-2-yl)sulfonamidderivate
NZ564608A (en) 2005-07-09 2009-09-25 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
US20100160286A1 (en) 2005-08-09 2010-06-24 Astrazeneca Uk Limited Ab Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes
CA2627813A1 (en) 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted pyrrolones as allosteric modulators of glucokinase
WO2007052843A1 (ja) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
KR101024227B1 (ko) 2005-11-21 2011-03-29 시오노기세이야쿠가부시키가이샤 11-β-히드록시스테로이드 탈수소효소 제 Ⅰ 형에 대한저해 활성을 갖는 헤테로시클릭 화합물
BRPI0707408A2 (pt) 2006-01-31 2011-05-03 Incyte Corp compostos de amido e seu uso como produtos farmacêuticos
WO2007107470A2 (en) 2006-03-22 2007-09-27 F. Hoffmann-La Roche Ag Pyrazoles as 11-beta-hsd-1
EP2010479A1 (en) 2006-04-07 2009-01-07 High Point Pharmaceuticals, LLC 11 beta-hydroxysteroid dehydrogenase type 1 active compounds
MX2008013285A (es) 2006-04-27 2008-10-24 Solvay Pharm Gmbh Uso novedoso de moduladores del receptor canabinoide cbx como moduladores de los canales de potasio.
WO2008012532A2 (en) 2006-07-27 2008-01-31 Astrazeneca Ab : pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
CN103288738B (zh) 2007-05-18 2016-03-16 盐野义制药株式会社 具有11β-羟基类固醇脱氢酶I型抑制活性的含氮杂环衍生物
AU2008277783B2 (en) 2007-07-17 2012-09-20 F. Hoffmann-La Roche Ag Inhibitors of 11beta-hydroxysteroid dehydrogenase
US20110060022A1 (en) 2007-11-06 2011-03-10 Astrazeneca Ab 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]Benzoic Acid - 465
MX2010008583A (es) 2008-02-04 2010-08-30 Astrazeneca Ab Novedosos formas cristalinas de acido 4-[4-(2-adamantilcarbamoil)- 5-ter-butil-pirazol-1-il]benzoico.
AU2009239794A1 (en) 2008-04-22 2009-10-29 Astrazeneca Ab Substituted pyrimidin-5-carboxamides 281
CN102300851A (zh) 2009-01-30 2011-12-28 阿斯利康(瑞典)有限公司 制备含羧基的吡唑酰氨基化合物597的新方法
US20110092526A1 (en) 2009-10-20 2011-04-21 Astrazeneca Ab Adamantyl Iminocarbonyl-Substituted Pyrimidines As Inhibitors Of 11-Beta-HSD1 826

Also Published As

Publication number Publication date
ES2423206T3 (es) 2013-09-18
JP5165688B2 (ja) 2013-03-21
AR063458A1 (es) 2009-01-28
WO2008053194A3 (en) 2008-10-02
RS51451B (sr) 2011-04-30
CN102603711A (zh) 2012-07-25
CN101573336B (zh) 2012-03-21
ES2347491T3 (es) 2010-10-29
AU2007315955A1 (en) 2008-05-08
US20090306075A1 (en) 2009-12-10
PT2086939E (pt) 2010-09-17
BRPI0717970A2 (pt) 2013-11-05
US7964618B2 (en) 2011-06-21
TW200827346A (en) 2008-07-01
WO2008053194A2 (en) 2008-05-08
DE602007008137D1 (en) 2010-09-09
ATE475649T1 (de) 2010-08-15
MX2009004707A (es) 2009-05-15
US8673938B2 (en) 2014-03-18
BRPI0717970B8 (pt) 2020-12-01
CA2668006C (en) 2016-05-24
HK1135090A1 (en) 2010-05-28
HRP20100522T1 (hr) 2010-11-30
BRPI0717970B1 (pt) 2019-10-22
UY30681A1 (es) 2008-07-03
SI2086939T1 (sl) 2010-10-29
RU2451674C2 (ru) 2012-05-27
EP2086939B8 (en) 2011-06-22
NZ576501A (en) 2011-03-31
RU2009115830A (ru) 2010-12-10
NO20091603L (no) 2009-05-28
CN101787016B (zh) 2013-08-28
CA2668006A1 (en) 2008-05-08
EP2233480A1 (en) 2010-09-29
PE20081487A1 (es) 2009-01-11
CL2007003176A1 (es) 2008-07-25
US20090312372A1 (en) 2009-12-17
US20080269288A1 (en) 2008-10-30
EP2086939B1 (en) 2010-07-28
EP2086939A2 (en) 2009-08-12
CY1110813T1 (el) 2015-06-10
DK2086939T3 (da) 2010-10-11
KR20090075865A (ko) 2009-07-09
CN101787016A (zh) 2010-07-28
CN101573336A (zh) 2009-11-04
CO6321130A2 (es) 2011-09-20
AU2007315955B2 (en) 2011-04-14
KR101465275B1 (ko) 2014-11-27
IL198231A0 (en) 2009-12-24
BRPI0717970C1 (pt) 2021-05-25
JP2010508338A (ja) 2010-03-18
EP2233480B1 (en) 2013-05-29

Similar Documents

Publication Publication Date Title
PL2086939T3 (pl) Pirydynokarboksyamidy jako inhibitory 11-beta-hsd1
GB0601961D0 (en) Method
GB0603081D0 (en) Method
SI2078001T1 (sl) Derivati diazepan-acetamida kot selektivni zaviralci 11 -hsd1
ZA200807046B (en) Beer-brewing method
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
GB0607317D0 (en) Method
GB0606147D0 (en) Method
GB0618001D0 (en) Method
GB0605323D0 (en) Method
GB0603008D0 (en) Method
GB0604018D0 (en) Method
GB0601699D0 (en) Method
GB0602986D0 (en) Method
GB0625782D0 (en) Method
GB0606954D0 (en) Method
GB0612014D0 (en) Method
GB0612342D0 (en) Method
GB0714941D0 (en) Inhibitors
GB0610949D0 (en) Method
GB0617274D0 (en) Method
HU0600278D0 (en) New process
GB0602830D0 (en) Method
GB0610338D0 (en) Method
GB0609901D0 (en) Method